References
- Mclaughlin VV, Mcgoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31
- Chemla D, Castelain V, Hervé P, et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314-31
- McLaughlin VV, Archer SL, Badesch DB, et al.; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society Inc.; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
- Matura LA, McDonough A, Carroll DL. Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage 2016;51:25-32
- Japan Intractable Diseases Information Center. Available at: http://www.nanbyou.or.jp/entry/1356#p09 [Last accessed on 20 June 2016]
- Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016;37:67-119
- Galiè N, Brundage BH, Ghofrani HA, et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
- Tay EL, Geok-Mui MK, Poh-Hoon MC, Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardio 2008;125:4167
- Affuso F, Palmieri EA, Di Conza P, et al. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006;108:429-31
- Palmieri EA, Affuso F, Fazio S, Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004;141:743-4
- Oudiz RJ, Brundage BH, Galiè N, et al.; PHIRST Study Group. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012;60:768-74
- Berman-Rosenzweig E, Arneson C, Klinger JR. Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. Pulm Circ 2014;4:45-52
- Mathai SC, Hassoun PM, Puhan MA, et al. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest 2015;147:188-97
- Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009;25:2479-85
- Aggarwal P, Patial RK, Negi PC, Marwaha R. Oral tadalafil in pulmonary artery hypertension: a prospective study. Indiana Heart J 2007;59:329-35
- Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J 2007;59:323-8
- Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid 2015;10:99-109
- Japan’s Ministry of Health, Labour and Welfare (MHLW). Re: Q & A on use-results surveys conducted as All-Case Surveillance and Early Post-Marketing Phase Vigilance (EPPV) for Prescription Drugs. 2009:1-7. Available at: http://www.pmda.go.jp/files/000153521.pdf [Last accessed on 15 March 2017]
- Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40-7S
- Berman-Rosenzweig E, Arneson C, Golden G. Relationship between dosing and common adverse events with tadalafil in patients with pulmonary arterial hypertension. Chest 2010;138:352A
- Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome – a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011;6:424-31
- Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014;19:700-6
- Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488-96